News | May 06, 2013

St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study

The MultiPoint Pacing study is designed to show improved effectiveness for patients when pacing multiple locations of the heart


May 6, 2013 — St. Jude Medical announced its first enrollment in its MultiPoint Pacing clinical study to build upon its first- to-market quadripolar pacing system. Patients will be implanted with the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D) and Quartet lead to assess pacing in multiple locations in the heart.

The study will evaluate outcome benefits such as improved hemodynamics and cardiac function in heart failure patients who receive cardiac resynchronization therapy (CRT). MultiPoint pacing provides the ability to deliver two left ventricular (LV) pacing pulses, either simultaneously or sequentially, rather than the standard single pulse for each pacing cycle. This may be beneficial in further increasing the responder rates to CRT because it may capture a larger area of the cardiac anatomy by engaging areas around already damaged tissue.

“The MultiPoint Pacing trial is a study of patients who may not receive benefit or are unresponsive to standard CRT single-point pacing. We are evaluating whether MPP can increase the potential for a successful CRT outcome by pacing in multiple locations in the heart,” said Gery Tomassoni, M.D., director of electrophysiology at Baptist Health Lexington in Lexington, Ky.

The prospective, randomized, double-blind, multi-center clinical study will enroll more than 500 patients at 50 centers in the United States. Implanted patients will receive the single pacing pulse available with the existing quadripolar systems for the first three months. After three months, patients will be classified as being responders or non-responders to single-point CRT pacing and then will be randomized to either a single or multi-point pacing group. Patients will be monitored for an additional six months, at which time responder rates will be compared between patients receiving MultiPoint pacing and single point pacing. 

For more information: www.sjm.com

 


Related Content

News | Pacemakers

May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device ...

Home May 25, 2023
Home
News | Pacemakers

May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted ...

Home May 12, 2023
Home
News | Pacemakers

May 1, 2023 — Medtronic plc, a global leader in healthcare technology, announced it has received U.S. Food and Drug ...

Home May 01, 2023
Home
News | Pacemakers

December 12, 2022 — The global pacemakers market is set to grow at a compound annual growth rate (CAGR) of 5.4% between ...

Home December 12, 2022
Home
News | Pacemakers

June 9, 2022 — Holes help make sponges and English muffins useful (and, in the case of the latter, delicious). Without ...

Home June 09, 2022
Home
News | Pacemakers

April 5, 2022 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber ...

Home April 05, 2022
Home
News | Pacemakers
February 16, 2022 – A revolutionary pacemaker that re-establishes the heart’s naturally irregular beat is set to be ...
Home February 16, 2022
Home
News | Pacemakers

August 9, 2021 — Boston Scientific is recalling INGENIO family of pacemakers and CRT-Ps due to the risk of incorrect ...

Home August 09, 2021
Home
News | Pacemakers

June 16, 2020 - Biotronik has today announced its commitment to giving physicians additional tools to pace in the His ...

Home June 16, 2020
Home
Videos | Pacemakers

This video illustrates how the Micra AV leadless pacemaker is delivered via catheter and enables atrioventricular (AV) ...

Home February 13, 2020
Home
Subscribe Now